• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Study Validates Cancer Blood Test Might Change The Case For Investing In Quest Diagnostics (DGX)

    Simply Wall St·10/11/2026 16:33:11
    Listen to the news
    • Quest Diagnostics reported new data in The Journal of Molecular Diagnostics showing its Haystack MRD liquid biopsy test accurately detects residual and recurrent disease across multiple solid tumor cancers, with high sensitivity and specificity versus standard blood biomarkers.
    • The study used real-world specimens from landmark DYNAMIC colorectal cancer trials and validated Haystack MRD across 23 solid tumor types, highlighting potential clinical demand for highly sensitive minimal residual disease monitoring.
    • We will now assess how Quest Diagnostics' investment narrative could be influenced by Haystack MRD's reported accuracy in detecting cancer recurrence.

    Look beyond Quest Diagnostics and compare Haystack MRD's potential with other healthcare leaders using our hand picked 34 healthcare AI stocks shaping the future of data driven diagnostics.

    Quest Diagnostics Investment Narrative Recap

    To own Quest Diagnostics, you need to believe the lab giant can keep growing higher value testing and consumer health while holding the line on costs. The near term swing factor is execution on automation and AI tools to continue offsetting wage pressure and reimbursement risk. The Haystack MRD data indicates that advanced oncology remains a meaningful operational focus.

    The biggest risk is still pricing and volume pressure from Medicare and public policy shifts, especially if wage inflation and Project Nova costs exceed Quest Diagnostics’ roughly 3% annual savings efforts. The new announcements do not materially change that risk reward balance in the short term.

    The Haystack MRD study is the clearest recent catalyst for this narrative. It relates directly to Quest Diagnostics’ push into complex oncology and data driven diagnostics. Clinical accuracy data in colorectal cancer and across many tumor types connects with the idea that more specialized tests can increase tests per requisition over time.

    At the same time, the Project Nova oversight role for Catherine Doherty, ahead of her planned 2027 retirement, is operationally important. Modernizing order to cash and related IT is central to the automation and digitization effort. Execution in this area influences whether advanced offerings like Haystack MRD contribute to margins or are offset by higher structural costs.

    How Haystack MRD Fits Into The Quest Diagnostics Numbers

    Quest Diagnostics' narrative projects revenues of US$13.3b and earnings of US$1.5b by 2029. This assumes revenue grows at about 4.8% a year and earnings rise by roughly US$0.4b from about US$1.1b today.

    The Haystack MRD data sits on top of this consensus story rather than rewriting it. Analysts are already baking in mid single digit annual top line expansion, a profit margin step up from 9.2% to 11.0%, and a P/E that drifts from 25.5x today to 22.5x on those 2029 earnings. In that context, a more accurate oncology assay is one potential way for Quest Diagnostics to support those projected earnings, not a separate growth engine that analysts are ignoring.

    Think about the levers that go into that US$1.5b earnings figure. Higher margin complex testing, more tests per requisition, and steady operating leverage from automation and AI tools are all part of the equation. Haystack MRD fits squarely into the first bucket. If clinicians use it to track residual disease in more tumor types, then a greater share of Quest Diagnostics' oncology work could shift to better reimbursed, data heavy assays rather than basic blood panels.

    At the same time, the current analyst consensus implies that the stock already prices in a fair amount of success. Revenues of US$13.3b, consistent profit margin expansion and a still premium P/E multiple all assume that oncology, consumer testing, and health system partnerships do their job. For a reader looking at Haystack MRD, the real question is not whether the test is promising. It is whether adoption can be meaningful enough within this framework to justify that existing earnings path.

    There is also an execution angle. Analysts expect earnings per share of US$13.0 by 2029 and a slight reduction in share count of 0.78% a year. Those forecasts rely on Project Nova and other automation projects producing the cost savings that offset wage inflation and IT spending. Haystack MRD becomes more attractive for shareholders if it adds volume and mix to a lab network that is already becoming cheaper to run on a per test basis.

    None of these numbers directly assign a revenue line to Haystack MRD, and they do not separate oncology earnings from the rest of the portfolio. For that reason, the test is best thought of as an optional kicker within a broader advanced diagnostics theme. If it scales across the 23 validated solid tumor types, it can help Quest Diagnostics defend its projected margin gains even if pricing pressure bites in other parts of the catalog.

    Uncover why Quest Diagnostics' fair value indicates a 7% potential upside to its current price that could narrow quickly.

    NYSE:DGX 1-Year Stock Price Chart
    NYSE:DGX 1-Year Stock Price Chart

    Exploring Other Perspectives

    The Simply Wall St Community has only two fair value estimates for Quest Diagnostics, stretching from about US$247 to nearly US$348 per share. This already shows how far opinions can diverge. When you also consider reimbursement risks and Haystack MRD as a potential oncology catalyst, the debate about future earnings resilience becomes even wider. Explore those differing views before drawing your own conclusion.

    Explore another Quest Diagnostics fair value estimate, including one that suggests as much as 51% upside from the current price!

    The Verdict Is Yours

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Quest Diagnostics?

    If Haystack MRD and the broader Quest Diagnostics story have sharpened your interest in data heavy healthcare and resilient cash flows, it can be useful to line that up against opportunities elsewhere in the market.

    • For readers who want potential mispricing with quality fundamentals, scan a focused list of 20 high quality undiscovered gems that may not yet be widely followed.
    • If capital protection sits high on your checklist, compare Quest Diagnostics with a 31 resilient stocks with low risk scores that scores well on resilience and balance sheet strength.
    • Income oriented investors can weigh Quest Diagnostics against a curated 8 dividend fortresses designed to surface companies combining higher yields with stability.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.